BioSpace News Archive

Sept. 27, 2021 12:30 UTC NEVE ILAN, Israel--( BUSINESS WIRE )-- NANO-X IMAGING LTD (" Nanox " or the " Company ,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium (CAC) solution as part of its population health offering. On August 10 th , 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD. Thi

- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots

Immunoforge (Co-CEOs Sung-min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Polymyositis.

Scopio Labs, provider of the world’s first full-field digital cell morphology solution, announced today the commercial launch of its FDA-cleared and CE-approved Full-Field Peripheral Blood Smear (FF-PBS) Application on the X100 platform.

Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in registrational phase III trial for the treatment of generalized myasthenia gravis (gMG).

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced that it will attend the 36th Annual North American Spine Society (“NASS”) Meeting held September 29 through October 2 at the Boston Convention and Exhibition Center.

Additionally, the companies are submitting non-dilutive grants that support combining their technologies in preclinical and clinical studies for various conditions related to central nervous system damage.

Ribon Therapeutics today announced it has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Scientists have created a new test to measure antibodies in girls who have received a vaccine for human papilloma virus, the leading cause of cervical cancer in women.

Dynavax Technologies Corporation today announced that it will participate in the following investor conferences. 2021 Cantor Virtual Global Healthcare Conference Dynavax Presentation: Thursday, September 30, 2021, 12:00 p.m. E.T.